The SMC restriction applies to patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors or protease inhibitors or when these options are compromised due to drug-drug interactions; raltegravir granules should be prescribed under the supervision of specialists in paediatric HIV.
The granules for oral suspension are licensed for use in patients weighing 3kg to 20kg and provide an alternative formulation for infants where chewable tablets are not suitable.